SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: dalroi who wrote (869)3/20/2000 1:19:00 AM
From: RWReeves  Respond to of 52153
 
>BTW asm.L is ridiculous undervalued if compared with AXO.TO
isnt it RWR ??<

Stefaan, stop rubbing it in. Maybe you can buy some ASM for me and keep it in your safe, kind of a poor mans' ADR, or in this case BDR? Hope CLL stays cheap long enough for me to snag some more tomorrow. Did EU investor's Karnovskys drop in London or what?

How come you can buy our stocks but we can't buy yours? GRRRRRRR! Time to look into dual nationality.

Prost!

RWR



To: dalroi who wrote (869)3/20/2000 12:09:00 PM
From: Jim Oravetz  Read Replies (1) | Respond to of 52153
 
3/20/00 10:02 ET Celltech Group (CLL) 45 +8 5/8: FDA Advisory Committee recommends approval of CLL's chemotherapy agent targeted directly to cancerous cells using monoclonal antibody technology

source:Briefing.com

Jim


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News